← Human Trials & Peer-Reviewed Studies
Ovulation induction using sequential letrozole/gonadotrophin in infertile women with PCOS: a randomized controlled trial
Plain-language guide to PMID 36566146 (2023): open-label randomized controlled trial study of HMG (Human Menopausal Gonadotropin) in 174 participants, pcos.
Key Facts
- PMID
- 36566146
- Journal
- Reproductive biomedicine online
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Dai X et al. (8 authors)
- DOI
- 10.1016/j.rbmo.2022.08.002
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at HMG (Human Menopausal Gonadotropin) in the context of pcos.
Who Took Part
The study group was 174 participants.
By PubMed's age tags, the people studied were teenagers, young adults and adults, women only.
This open-label randomized controlled trial comparing sequential letrozole/HMG and letrozole alone included 174 participants enrolled from August 2019 to January 2020 at the Union Hospital of Tongji Medical College, Huazhong University of Science and Technology.
Infertile women aged between 18 and 40 years who met Rotterdam criteria for PCOS and without other known causes of infertility were selected for this study.
How the Study Was Run
The researchers set it up as a randomized and open-label study.
The participants were allocated by chance, so the HMG (Human Menopausal Gonadotropin) group and the comparison group should start out alike.
Everyone knew when HMG (Human Menopausal Gonadotropin) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
The pregnancy outcome was recorded after one treatment cycle.
What Was Measured
PubMed files the paper under topics including Letrozole, Infertility, Female, Polycystic Ovary Syndrome, Clomiphene, Fertility Agents, Female, Gonadotropins and Ovulation Induction.
The authors tagged it with the keywords Human menopausal gonadotrophin and Sequential therapy.
What This Means in Plain Language
The paper is a randomized and open-label study of HMG (Human Menopausal Gonadotropin) in 174 participants in people with pcos.
Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Reproductive biomedicine online), a journal based in Netherlands.
More context: the HMG (Human Menopausal Gonadotropin) compound page, PCOS research.
Our Notes on the Compound
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.